Clinical Application of Radical Urethrectomy Combined with Primary Urethral Reconstruction in Urethral Cancer

Li H1

Research Type

Clinical

Abstract Category

Uro-Oncology

Abstract 865
Non Discussion Abstracts
Scientific Non Discussion Abstract Session 400
Surgery Female Robotic-assisted genitourinary reconstruction Clinical Trial Outcomes Research Methods
1. Shenzhen University Affiliated Huanan Hospital
Links

Abstract

Hypothesis / aims of study
Hypothesis: Radical urethrectomy with vaginal wall pedicle flap urethral reconstruction achieves complete tumor eradication while preserving or restoring urinary continence in female patients with primary urethral cancer (PUC), offering a safe and effective surgical approach.  
Aim of Study: This study describes the clinical outcomes of vaginal wall pedicle flap urethral reconstruction following radical urethrectomy for female PUC, evaluating its oncological efficacy, urinary continence rates, and long-term safety.
Study design, materials and methods
Study Design, Materials, and Methods: A retrospective analysis was conducted on 223 female patients (mean age: 58.3 years; range: 26–83 years) who underwent radical urethrectomy for PUC between August 2010 and December 2022. All tumors were excised with a surgical margin exceeding 2 cm. Patients were stratified into two cohorts:  
1. Early-stage group (n=211): Primary urethral reconstruction was performed using a vaginal wall pedicle flap with preservation of the native bladder sphincter.  
2. Total urethrectomy group (n=12): Patients requiring full urethral excision underwent staged reconstruction, including bladder neck reconstruction, artificial urinary sphincter implantation, and tubularized vaginal wall pedicle flap urethroplasty.  
Postoperative follow-up spanned 2–14 years (median: 8.2 years), with assessments for tumor recurrence (clinical exams, imaging) and urinary continence (24-hour pad test). Complications, including flap viability and sphincter function, were systematically documented.
Results
Results:  
- Oncological Outcomes: No local or distant tumor recurrence was observed during the follow-up period.  
- Urinary Continence: Complete continence (0 g/24-hour pad weight) was achieved in 222 patients (99.6%). One patient (0.4%) in the total urethrectomy group exhibited mild stress incontinence (5 g/24-hour pad weight).  
- Surgical Safety: No major perioperative complications (e.g., flap necrosis, urethral stricture, or infection) occurred. All artificial sphincters (n=12) remained functional without mechanical failure or revision.
Interpretation of results
Interpretation of Results:  
The absence of recurrence validates the adequacy of ≥2 cm surgical margins for PUC resection. The vaginal wall pedicle flap technique demonstrated dual advantages:  
1. Anatomic Preservation: In early-stage cases, sphincter-sparing reconstruction maintained physiological urinary control mechanisms.  
2. Functional Restoration: For advanced tumors requiring total urethrectomy, the combination of bladder neck reconstruction, artificial sphincters, and tubularized flaps successfully replicated urethral anatomy and continence function.  
The 99.6% continence rate highlights the procedure’s precision in balancing radical oncologic resection with functional preservation. The lack of flap-related complications underscores the reliability of vaginal tissue for reconstruction, attributable to its vascularity and proximity to the surgical site.
Concluding message
Concluding Message:  
Vaginal wall pedicle flap urethral reconstruction following radical urethrectomy is a definitive treatment for female PUC, offering unparalleled oncological control and exceptional functional outcomes. The technique’s adaptability—preserving sphincters in early-stage disease and integrating artificial sphincters in advanced cases—ensures tailored, patient-centric care. With no recurrences and near-perfect continence rates over a median 8.2-year follow-up, this approach establishes a new benchmark for treating female urethral cancer, prioritizing both survival and quality of life. These findings advocate for its adoption as a standard surgical strategy, particularly in centers specializing in urologic oncology and reconstructive surgery. Further multicenter studies are warranted to validate these results across diverse populations.
Disclosures
Funding National Clinical Trial Yes Public Registry No RCT No Subjects Human
16/07/2025 07:00:07